Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular oncology"
DOI: 10.1002/1878-0261.70019
Abstract: Epigenetic regulators, such as the SWI/SNF complex, with important roles in tissue development and homeostasis, are frequently mutated in cancer. ARID1A, a subunit of the SWI/SNF complex, is mutated in approximately 20% of all bladder… read more here.
Keywords: dna damage; multidimensional omics; cell; arid1a deficient ... See more keywords
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Sign Up to like & getrecommendations! Published in 2020 at "Gastric Cancer"
DOI: 10.1007/s10120-020-01094-0
Abstract: Background AT-rich interactive domain 1A ( ARID1A ) is a tumor suppressor gene that is frequently mutated in gastric cancer (GC). Although ARID1A mutations are not a druggable target for conventional treatments, novel therapeutic strategies… read more here.
Keywords: deficient; ezh2 inhibitors; arid1a deficient; cancer ... See more keywords
Targeting USP9X-AMPK axis in ARID1A-deficient hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Cellular and molecular gastroenterology and hepatology"
DOI: 10.1016/j.jcmgh.2022.03.009
Abstract: BACKGROUND & AIMS Hepatocellular carcinoma(HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-Rich Interaction Domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in… read more here.
Keywords: hepatocellular carcinoma; hcc; targeting usp9x; usp9x ampk ... See more keywords
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2019.10.002
Abstract: OBJECTIVE Ovarian clear cell carcinoma (OCCC) is often resistant to conventional, standard chemotherapy using cytotoxic drugs. OCCC harbors a unique genomic feature of frequent (approximately 50%) ARID1A deficiency. The present study was performed to investigate… read more here.
Keywords: gemcitabine; arid1a deficient; deficient occc;
ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosis
Sign Up to like & getrecommendations! Published in 2025 at "Cell Death and Differentiation"
DOI: 10.1038/s41418-025-01510-x
Abstract: ARID1A, a subunit of the SWI/SNF chromatin-remodeling complex, functions as a tumor suppressor in various cancer types. Owing to its high frequency of inactivating mutations, ARID1A has emerged as a promising target for the development… read more here.
Keywords: iron; arid1a loss; inducing ferroptosis; crc ... See more keywords
ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.
Sign Up to like & getrecommendations! Published in 2024 at "Cancer research"
DOI: 10.1158/0008-5472.can-23-2846
Abstract: Neoantigen-based immunotherapy is an attractive potential treatment for previously intractable tumors. To effectively broaden the application of this approach, stringent biomarkers are crucial to identify responsive patients. ARID1A, a frequently mutated subunit of SWI/SNF chromatin… read more here.
Keywords: deficient tumors; resistance; arid1a deficient; targeted therapy ... See more keywords
Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/0008-5472.can-24-1611
Abstract: The arachidonic acid pathway is a metabolic vulnerability in ARID1A-deficient colorectal cancer that can be targeted with aspirin to suppress tumor growth and enhance sensitivity to immunotherapy, providing a promising therapeutic strategy. read more here.
Keywords: colorectal cancer; cancer; arachidonic acid; deficient colorectal ... See more keywords
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.999626
Abstract: ARID1A is frequently mutated in colorectal cancer (CRC) cells. Loss of ARID1A function compromises DNA damage repair and increases the reliance of tumor cells on ATR-dependent DNA repair pathways. Here, we investigated the effect of… read more here.
Keywords: arid1a deficient; vulnerability arid1a; atr inhibitor; deficient ... See more keywords
Morphological, clinical and molecular characteristics in ARID1a‑deficient microsatellite‑stable oesophageal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Oncology letters"
DOI: 10.3892/ol.2023.13840
Abstract: Publications describe the relevance of the AT-rich interactive domain-containing protein 1A (ARID1a) mutation in gastric adenocarcinoma, which occurs predominantly in the microsatellite instable (MSI)- and Epstein-Barr virus (EBV)-associated subtypes. It is unclear whether potential therapeutic,… read more here.
Keywords: arid1a deficient; microsatellite stable; oesophageal adenocarcinoma; loss ... See more keywords
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "PeerJ"
DOI: 10.7717/peerj.12750
Abstract: Background Genetic alterations in ARID1A were detected at a high frequency in cholangiocarcinoma (CCA). Growing evidence indicates that the loss of ARID1A expression leads to activation of the PI3K/AKT pathway and increasing sensitivity of ARID1A-deficient… read more here.
Keywords: akt pathway; pi3k akt; arid1a deficient; cca ... See more keywords